Personalized T-cell therapy for advanced solid tumors with TP53 R248Q mutation
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a personalized cell therapy that uses your own immune cells, modified to target a specific genetic mutation found in some tumors. It aims to see if this treatment can shrink tumors or slow their growth in people with advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have lung cancer, colorectal cancer, pancreatic cancer, or another solid tumor that has progressed after standard treatment.
- Genetic testing has shown that your tumor has a specific change called TP53 R248Q.
- You are able to do everyday activities without major help (ECOG 0-1).
- You have at least one tumor that can be measured on a scan.
- You can provide a recent tumor sample (within 2 years).
- Your blood, liver, and kidney function are within acceptable levels.
- If you have brain metastases, they must be small (less than 3 cm) and not cause symptoms.
- You have not had certain prior treatments or other cancers recently.
- You must agree to use effective birth control during and for a year after the treatment.
- You do not have active infections like hepatitis, HIV, or syphilis.
- You are not pregnant or breastfeeding.
- You have not had a bone marrow or organ transplant.
- You do not have severe heart, lung, or autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy for people with advanced solid tumors that have not responded to standard treatments. It targets tumors with specific genetic markers (KRAS or NRAS G12D and HLA-A*11:01) to see if it can shrink or slow the cancer.
This study tests a new treatment using your body's own immune cells (called tumor-infiltrating lymphocytes) that are taken from your tumor, grown in a lab, and then put back into you. It's for people with advanced solid tumors who have run out of standard options.
This early-phase trial tests whether combining a lab-made CAR-DC cancer vaccine with immune checkpoint medicines can shrink tumors that have specific genetic changes. It’s meant for people with advanced or returning (relapsed) solid tumors or certain lymphomas that match required tumor markers.
This trial tests a new drug called LG00313112 in people with advanced solid tumors that have a specific genetic change called TP53 Y220C. The drug is designed to target tumors with this mutation, and the study aims to see if it can help shrink or control the cancer.
This Phase 1 study tests a lab-made immune cell treatment made from your own blood cells (T cells) to fight advanced lung cancer or other solid tumors. You may be eligible if your tumor can be biopsied and the lab can successfully prepare T cells that strongly recognize and attack your cancer.
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.